## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `retatrutide-glp1-gut`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/retatrutide-glp1-gut/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide-glp1-gut/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/retatrutide-glp1-gut/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/retatrutide-glp1-gut/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/retatrutide-glp1-gut/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/retatrutide-glp1-gut/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `retatrutide-glp1-gut` v2 · content_hash `62398ce51566515e…` · thread_head genesis · 24 DIVs
- **thesis (c1):** Retatrutide delays gastric emptying in human studies
  - c2 [human/active] Phase 2 trials show GI side effects higher with retatrutide than placebo
  - c3 [human/active] GLP-1 class linked to 3.67x higher gastroparesis risk in population study
  - c4 [human/active] No serious gastroparesis reported in retatrutide trials
  - c5 [anecdotal/active] Reddit users report gastroparesis symptoms at low retatrutide doses
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/retatrutide-glp1-gut/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/retatrutide-glp1-gut/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `retatrutide-glp1-gut`
- **title:** Retatrutide for GLP-1 Gut Damage: Weight Loss Pathways vs Gastric Slowing Evidence
- **url:** https://miscsubjects.com/a/retatrutide-glp1-gut
- **register:** source_ledger
- **updated:** 2026-07-17T02:41:17.200Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have GLP-1 gut damage / gastroparesis

If GLP-1 agonists have slowed your gastric emptying, the core issue is delayed stomach emptying. Food stays longer in the stomach. This leads to nausea, bloating, early fullness, and sometimes vomiting. The mechanism is the GLP-1 pathway itself, which slows motility to reduce calorie intake. No tissue breakdown like disc degeneration occurs here. Instead, the drug action directly affects gut motility. Rapid weight loss from these drugs can also reduce muscle mass, which may compound metabolic issues over time. The condition persists if the slowing effect continues without dose adjustment or cessation.

## Why Retatrutide might help you

1. You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.
2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.
3. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.
4. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.

Retatrutide activates GLP-1, GIP, and glucagon receptors. This triple action drives greater weight reduction than single or dual agonists in phase 2 data. If excess weight adds mechanical stress elsewhere in your body, the resulting loss could ease that load. However, retatrutide also delays gastric emptying via its GLP-1 component. This is the same pathway linked to gastroparesis symptoms in the class. For someone already experiencing GLP-1 gut damage, the weight loss benefit sits alongside the risk of further or prolonged motility slowing. No direct repair of damaged gut motility is shown.

## Why GLP-1 agonists (class) matters for you

**Drug:** GLP-1 agonists (class)
**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.
**Therefore for you:** This drug reduces load through weight loss and supports metabolism but suppresses gastric motility signals, which trades off repair potential for your gut condition by extending the slowing effect.

GLP-1 agonists deliver metabolic improvements including appetite reduction and better glucose control. These come with the known tradeoff of slowed gastric emptying. In people with existing symptoms, this can worsen or prolong gastroparesis-like effects. Muscle loss during fast weight drop may further affect overall repair capacity. The class supports metabolic repair pathways while directly contributing to the motility issue central to your described condition.

## How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- **Retatrutide** → metabolic load / body weight

Retatrutide combines weight-loss driven load reduction with the same GLP-1 gut-slowing mechanism found in the broader agonist class. The metabolic benefit layer may ease body-wide mechanical stress if weight is a factor. The gut layer remains a direct class effect rather than a fix. No synergy for reversing existing gastroparesis is described; the compound aligns with the drug class profile.

## What the evidence actually shows

Human trials (phase 2) report gastrointestinal side effects including nausea, vomiting, diarrhea, and constipation in retatrutide groups, higher than placebo and often during dose escalation. One study specifically measured delayed gastric emptying with retatrutide. No serious GI disorders such as gastroparesis or bowel obstruction appeared in the reported trial data. Population studies on the GLP-1 class show elevated risk of gastroparesis diagnosis (around 3.67 times higher in one analysis of weight-loss users). Preclinical data confirm gastric emptying delay in animal models. No human trials test retatrutide as a treatment for gastroparesis; all data position it as a potential contributor via the same pathway.

## What scientists say

Researchers note that GLP-1 driven slowing of gastric emptying explains most GI side effects across the class, including retatrutide. Dose titration reduces incidence and severity in trials. Experts state there is no evidence for permanent gastroparesis from these drugs, though symptoms can persist while on treatment. People with pre-existing gastroparesis are typically excluded from incretin trials due to risk of worsening.

## What people say on Reddit

Users on r/Retatrutide report gastroparesis-like symptoms even at low doses below trial levels, including severe fullness, inability to eat, and need for hydration support. Some describe symptoms starting after initial tolerance and lasting weeks after dose changes. Others note symptoms improve with time or dose reduction but recur with escalation.

## What people say on X

Posts describe similar GI slowdown experiences with retatrutide, often comparing intensity to other GLP-1 drugs. Anecdotes mention temporary nature tied to dose ramps and advise on managing with diet adjustments. No widespread reports of permanent damage appear in sampled discussions.

## What we do not know

Long-term human data on retatrutide beyond 48 weeks remain limited. No dedicated trials examine retatrutide in patients with existing GLP-1 induced gastroparesis. The balance of weight-loss benefit versus motility effects in this specific population is unstudied. Animal data on glucagon component effects on gut motility are preliminary.

## Safety and limits

Retatrutide shares the GLP-1 class GI risk profile. Symptoms are most common early and with dose increases. Discontinuation rates due to side effects reach 6-26% in related trials. No data support use for reversing gut damage; the compound is studied for weight management. Individual response varies widely. Monitoring for dehydration and nutritional intake is noted in reports when symptoms occur.

## Claims (5)

- **c1** [human w=0.8] Retatrutide delays gastric emptying in human studies
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [human w=0.8] Phase 2 trials show GI side effects higher with retatrutide than placebo
  - who_claims: grok/grok-4.3
  - sources: s2
- **c3** [human w=0.8] GLP-1 class linked to 3.67x higher gastroparesis risk in population study
  - who_claims: grok/grok-4.3
  - sources: s3
- **c4** [human w=0.8] No serious gastroparesis reported in retatrutide trials
  - who_claims: grok/grok-4.3
  - sources: s4
- **c5** [anecdotal w=0.3] Reddit users report gastroparesis symptoms at low retatrutide doses
  - who_claims: grok/grok-4.3
  - sources: s5

## Voxel graph (5 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/retatrutide-glp1-gut/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (5)
- chain valid: yes · head: `c3e708760498246f`

### s1 · pubmed · ok
- title: The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying
- url: https://pubmed.ncbi.nlm.nih.gov/37311727/
- summary: Phase 1/2 study measuring gastric emptying delay with retatrutide
- quote: retatrutide delays gastric emptying
- claim_ids: c1
- hash: `03ad663c6225b0d3`

### s2 · pubmed · ok
- title: Efficacy and safety of retatrutide
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/
- summary: Safety data from retatrutide trials
- quote: Gastrointestinal side effects such as diarrhea, vomiting, and constipation had a higher incidence in the retatrutide groups
- claim_ids: c2
- hash: `5cf94403bfcbefd3`

### s3 · news · ok
- title: Weight-loss drugs linked to stomach paralysis
- url: https://www.med.ubc.ca/news/weight-loss-drugs-linked-to-stomach-paralysis-other-serious-gastrointestinal-conditions/
- summary: UBC study on GLP-1 agonists and GI risks
- quote: 3.67 times higher risk of gastroparesis
- claim_ids: c3
- hash: `6a51f9ece064dbd9`

### s4 · news · ok
- title: Retatrutide Produces Greatest Weight Loss
- url: https://mdedge.com/endocrinology/article/272111/obesity/retatrutide-produces-greatest-weight-loss
- summary: Review of incretin trial safety data
- quote: no serious GI disorders, such as bowel obstruction or gastroparesis, were reported in any of the 26 trials
- claim_ids: c4
- hash: `94cff04d432c3c86`

### s5 · reddit · ok
- title: Gastroparesis on low dose?
- url: https://www.reddit.com/r/Retatrutide/comments/1k1mq3e/gastroparesis_on_low_dose/
- summary: User report of symptoms at low dose
- quote: In my case, it's pure gastroparesis (slowed gastric emptying), which is a known effect of retatrutide
- claim_ids: c5
- hash: `c3e708760498246f`

## Provenance (2 model passes)
- chain valid: yes · head: `9f788d55de33c133`

- write · grok/grok-4.3 · 2026-06-30T00:59 · hash `dd6bfc4da6db`
- voxel_divide · owner · 2026-07-17T02:41 · hash `9f788d55de33`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/retatrutide-glp1-gut/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/retatrutide-glp1-gut/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"retatrutide-glp1-gut","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest retatrutide-glp1-gut|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim retatrutide-glp1-gut|tier|assertion`
- **iMessage ask:** `retatrutide-glp1-gut|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `retatrutide-glp1-gut`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide-glp1-gut/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/retatrutide-glp1-gut/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*